---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-014000"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T14:55:41.621636+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics Q3 cash $101.9M; uproleselan Phase 3 enrollment nearing completion

## Summary
- Cash and cash equivalents $101.9M at Sept 30, 2021, down from $137.0M at Dec 31, 2020.
- R&D expenses increased to $13.3M from $10.7M YoY, driven by Phase 3 trial costs.
- Phase 3 trial of uproleselan in relapsed/refractory AML nearing enrollment completion; top line data after 2022.
- Data published in BLOOD showed 69% MRD negative rate in evaluable relapsed/refractory AML patients.
- New CEO Harout Semerjian appointed effective August 6, 2021.

## SEC filing metadata
- accession: 0001558370-21-014000
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837021014000/0001558370-21-014000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837021014000/glyc-20211102x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-014000
- JSON: https://secwatch.observer/filing/0001558370-21-014000.json
- Plain text: https://secwatch.observer/filing/0001558370-21-014000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.